Pantalone, DO, ECNU Incretin-based drug therapies such as glucagon-like peptide-1 (GLP-1) receptor agonists and dual glucose-dependent insulinotropic peptide and GLP-1 receptor agonists are rapidly becoming first-line options for treating type 2 diabetes
What to Expect: General Timeline Outcomes differ from person to person depending on age, starting hormone levels, and how consistently you follow the protocol
Beyond lowering blood sugar, metformin can also help reduce the risk of diabetes complications like nerve damage, kidney issues, and cardiovascular problems
I made a single, simple post
Researchers posit that GHRP-2 and GHRP-6 may activate the receptors by interacting with the enzyme phospholipase C (PLC), which cuts a specific membrane molecule (PIP) into two smaller signaling molecules called IP and DAG